Zoetis Inc. (LON:0M3Q)
146.93
+3.73 (2.60%)
At close: Sep 30, 2025
Zoetis Revenue
Zoetis had revenue of $2.46B USD in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $9.39B, up 5.27% year-over-year. In the year 2024, Zoetis had annual revenue of $9.26B with 8.33% growth.
Revenue (ttm)
$9.39B
Revenue Growth
+5.27%
P/S Ratio
7.03
Revenue / Employee
$680.07K
Employees
13,800
Market Cap
48.15B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Zoetis News
- 3 days ago - Zoetis: Much Bark, Little Bite - The Stock Remains Pricey - Seeking Alpha
- 3 days ago - Top 15 High-Growth Dividend Stocks For October 2025 - Seeking Alpha
- 5 days ago - Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment - GuruFocus
- 5 days ago - Zoetis granted conditional approval of Dectomax-CA1 for parasitic infection in cattle - Seeking Alpha
- 5 days ago - Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle - Business Wire
- 5 days ago - Zoetis (ZTS) Gains Conditional FDA Approval for Cattle Treatment - GuruFocus
- 8 days ago - ZTS Quantitative Stock Analysis - Warren Buffett - Nasdaq
- 9 days ago - Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing - Nasdaq